Webcasts Event RSS
Upcoming Events Past Events
Halozyme To Host Fourth Quarter And Full Year 2019 Financial Results Webcast And Conference Call
February 24, 2020
View the live Webcast
38th Annual J.P. Morgan Healthcare Conference
January 16, 2020
View the live Webcast
Halozyme To Host Third Quarter 2019 Financial Results Webcast And Conference Call
November 12, 2019
View the live Webcast

Investor Materials

Thumb Date Download
July 20, 2018 Corporate Presentation 575 KB
January 1, 2018 2018 Annual Report 939 KB
December 31, 2017 2017 Annual Report 3.18 MB
July 24, 2016 2016 Annual Report 4.75 MB
July 23, 2016 2015 Annual Report 5.24 MB
July 21, 2016 2014 Annual Report 2.13 MB

Recent News

Date Title Press Release RSS
Halozyme To Host Fourth Quarter And Full Year 2019 Financial Results Webcast And Conference Call 02/10/20
Halozyme Provides 2020 Business Update And Financial Guidance 01/14/20
Halozyme Therapeutics To Present At The 38th Annual J.P. Morgan Healthcare Conference 01/03/20
Data From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's ENHANZE® Drug Delivery Technology To Be Presented At San Antonio Breast Cancer Symposium 12/12/19
See More

Investor Contacts

Al Kildani
Vice President, Investor Relations
& Corporate Communications
Phone: 858-704-8122
Email: akildani@halozyme.com
media@halozyme.com
ir@halozyme.com

Useful Links

Contact Info


Office:

Halozyme
11388 Sorrento Valley Road
San Diego, CA 92121
Phone: 858.794.8889
info@halozyme.com

Recent News

February 10, 2020 Halozyme To Host Fourth Quarter And Full Year 2019 Financial Results Webcast And Conference Call
January 14, 2020 Halozyme Provides 2020 Business Update And Financial Guidance
January 3, 2020 Halozyme Therapeutics To Present At The 38th Annual J.P. Morgan Healthcare Conference
Copyright© 2015-2019. Halozyme, Inc. All rights reserved. All trademarks belong to their respective owners.
Powered By Q4 Inc. 5.28.0.10

Notice

You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.

Ok